NAVB vs. MYMD, VRAX, BMRA, GOVX, PHAS, NEXI, BACK, MDXH, SNES, and LUCY
Should you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include MyMD Pharmaceuticals (MYMD), Virax Biolabs Group (VRAX), Biomerica (BMRA), GeoVax Labs (GOVX), PhaseBio Pharmaceuticals (PHAS), NexImmune (NEXI), IMAC (BACK), MDxHealth (MDXH), SenesTech (SNES), and Innovative Eyewear (LUCY). These companies are all part of the "medical" sector.
MyMD Pharmaceuticals (NASDAQ:MYMD) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings.
MyMD Pharmaceuticals and Navidea Biopharmaceuticals both received 0 outperform votes by MarketBeat users.
In the previous week, MyMD Pharmaceuticals had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 2 mentions for MyMD Pharmaceuticals and 1 mentions for Navidea Biopharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled MyMD Pharmaceuticals'average media sentiment score.
9.6% of MyMD Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 2.6% of MyMD Pharmaceuticals shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
MyMD Pharmaceuticals has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.
MyMD Pharmaceuticals' return on equity of 0.00% beat Navidea Biopharmaceuticals' return on equity.
MyMD Pharmaceuticals has higher earnings, but lower revenue than Navidea Biopharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than MyMD Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
MyMD Pharmaceuticals beats Navidea Biopharmaceuticals on 6 of the 10 factors compared between the two stocks.
Get Navidea Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Navidea Biopharmaceuticals Competitors List
Related Companies and Tools
